Paper37726886
Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.
Panneerselvam S and 6 others. Cell Adh Migr, 2023. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options. Papers, record 37726886. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37726886
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.
- PubMed
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Molecular Targeted Therapy | |
| Mutation |
Source PubMed
References162
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21135505 | Activation of the unfolded protein response and autophagy after hepatitis C virus infection suppresses innate antiviral immunity in vitro. | J Clin Invest | 2011 | https://conductscience.org/library/papers/21135505 | PubMed |
| 2 | 20196837 | Association between C282Y and H63D mutations of the HFE gene with hepatocellular carcinoma in European populations: a meta-analysis. | J Exp Clin Cancer Res | 2010 | https://conductscience.org/library/papers/20196837 | PubMed |
| 3 | 32730345 | Increased hepatic and circulating chemokine and osteopontin expression occurs early in human NAFLD development. | PLoS One | 2020 | https://conductscience.org/library/papers/32730345 | PubMed |
| 4 | 33808740 | A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC? | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/33808740 | PubMed |
| 5 | 33748726 | NAFLD and MAFLD as emerging causes of HCC: A populational study. | JHEP Rep | 2021 | https://conductscience.org/library/papers/33748726 | PubMed |
| 6 | 34629183 | Chaperone-mediated autophagy and disease: Implications for cancer and neurodegeneration. | Mol Aspects Med | 2021 | https://conductscience.org/library/papers/34629183 | PubMed |
| 7 | 28137313 | The evolving concept of liver cancer stem cells. | Mol Cancer | 2017 | https://conductscience.org/library/papers/28137313 | PubMed |
| 8 | 36293184 | Cancer Stem Cells in Hepatocellular Carcinoma: Intrinsic and Extrinsic Molecular Mechanisms in Stemness Regulation. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36293184 | PubMed |
| 9 | 34440803 | NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome. | Cells | 2021 | https://conductscience.org/library/papers/34440803 | PubMed |
| 10 | 34329775 | Treatment Algorithm for Managing Chronic Hepatitis B Virus Infection in the United States: 2021 Update. | Clin Gastroenterol Hepatol | 2022 | https://conductscience.org/library/papers/34329775 | PubMed |
| 11 | 34506016 | CK19 Predicts Recurrence and Prognosis of HBV Positive HCC. | J Gastrointest Surg | 2022 | https://conductscience.org/library/papers/34506016 | PubMed |
| 12 | 23712051 | Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. | J Hepatol | 2013 | https://conductscience.org/library/papers/23712051 | PubMed |
| 13 | 31728429 | Hepatocellular carcinoma in alcoholic and non-alcoholic fatty liver disease-one of a kind or two different enemies? | Transl Gastroenterol Hepatol | 2019 | https://conductscience.org/library/papers/31728429 | PubMed |
| 14 | 35938354 | Blockade of T-cell receptor with Ig and ITIM domains elicits potent antitumor immunity in naturally occurring HBV-related HCC in mice. | Hepatology | 2023 | https://conductscience.org/library/papers/35938354 | PubMed |
| 15 | 25421688 | Detection of epigenetic aberrations in the development of hepatocellular carcinoma. | Methods Mol Biol | 2015 | https://conductscience.org/library/papers/25421688 | PubMed |
| 16 | 22655206 | Hepatocellular carcinoma: focus on different aspects of management. | ISRN Oncol | 2012 | https://conductscience.org/library/papers/22655206 | PubMed |
| 17 | 27006468 | C-terminal truncated hepatitis B virus X protein promotes hepatocellular carcinogenesis through induction of cancer and stem cell-like properties. | Oncotarget | 2016 | https://conductscience.org/library/papers/27006468 | PubMed |
| 18 | 28595519 | T-cell-associated immunotherapy: a promising strategy for the treatment of hepatocellular carcinoma. | Immunotherapy | 2017 | https://conductscience.org/library/papers/28595519 | PubMed |
| 19 | 24457013 | Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. | Semin Cancer Biol | 2014 | https://conductscience.org/library/papers/24457013 | PubMed |
| 20 | 28626852 | Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology). | J Gastrointest Cancer | 2017 | https://conductscience.org/library/papers/28626852 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42934724 | The evolving role of TP53 mutation in hepatocellular carcinoma (HCC). | Cancer Cell Int | 2026 | https://conductscience.org/library/papers/42934724 | PubMed |
| 42883895 | Unveiling Novel Molecular Candidate Targets of Loratadine, Raloxifene, and Sorafenib in Hepatocellular Carcinoma. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42883895 | PubMed |
| 41589205 | Role of insulin-like growth factor/receptor signaling in hepatocellular carcinoma. | Hepatol Forum | 2026 | https://conductscience.org/library/papers/41589205 | PubMed |
| 40702000 | RBM17 promotes hepatocellular carcinoma progression by regulating lipid metabolism and immune microenvironment: implications for therapeutic targeting. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40702000 | PubMed |
| 40584445 | Effect of Crocus sativus L. (saffron) and Rosmarinus officinalis L. (rosemary) in hepatocellular carcinoma: A narrative review of current evidence and prospects. | Iran J Basic Med Sci | 2025 | https://conductscience.org/library/papers/40584445 | PubMed |
| 39598228 | The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges. | Life (Basel) | 2024 | https://conductscience.org/library/papers/39598228 | PubMed |
| 38634139 | The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance. | Technol Cancer Res Treat | 2024 | https://conductscience.org/library/papers/38634139 | PubMed |
| 38612504 | Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38612504 | PubMed |
| 38148326 | Bile acids, gut microbiota, and therapeutic insights in hepatocellular carcinoma. | Cancer Biol Med | 2023 | https://conductscience.org/library/papers/38148326 | PubMed |
Genes146
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37726886
GET https://conductscience.org/api/papers/v1/37726886/references?page=2